Study of the Feasibility to Derive Vaccine From Tumor Tissue in Patients With Non-Small Cell Lung Cancer

A Phase II Study of the Feasibility to Derive Autologous Vaccine (HSPPC-96) From Tumor Tissue for Clinical Administration in Patients With Resectable Non-Small Cell Lung Cancer

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00098085

Enrollment

Registered

2004-12-06

Start date

2003-09-30

Completion date

Unknown

Last updated

2009-03-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-Small-Cell Lung Carcinoma, Lung Cancer, Pulmonary Cancer

Keywords

Lung cancer, Non-small cell lung cancer, Pulmonary, Immunotherapy, Vaccine

Brief summary

Antigenics is enrolling patients in a Phase II study testing the feasibility to derive an autologous investigational vaccine (HSPPC-96) from the tumor tissue of patients with resectable non-small cell lung cancer. Vaccine production will be attempted on all patients who undergo surgery and meet all inclusion/exclusion criteria.

Detailed description

Antigenics is enrolling patients in a Phase II study testing the feasibility to derive an autologous investigational vaccine (HSPPC-96) from the tumor tissue of patients with resectable non-small cell lung cancer. All patients will undergo surgery to remove the tumor and will be followed for recurrence and overall survival. The primary goal of this trial is to determine if HSPPC-96 can be made from the tumor tissue of patients with resectable non-small cell lung cancer. The secondary goals are to further characterize the safety and efficacy profile, to evaluate disease recurrence in patients receiving, and to evaluate overall survival in patients receiving HSPPC-96. HSPPC-96 is an investigational, immunotherapeutic agent made from an individual patient's own tumor, which is collected at the time of surgery. A portion of the tumor tissue is sent to Antigenics' manufacturing facility where it will undergo processing to create a vaccine. This vaccine may help the patient's immune system attack cancerous cells while leaving healthy cells alone.

Interventions

BIOLOGICALHSPPC-96

Study design

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

This is a summary of criteria. Only the Principal Investigator can determine eligibility. Inclusion Criteria: * Suspected non-small cell lung cancer, Stage IB, Stage II, or Stage IIIA * Tumor size \> 3x3 cm or equivalent to a 9 cm² lesion * Scheduled surgery with curative intent * At least 18 years of age * Must not be pregnant or breast feeding * Agree to not receive any other investigative agent at any time while enrolled in this study

Exclusion criteria

* Previous treatment for non-small cell lung cancer * Clinical signs or symptoms of brain metastases * History of immune suppression or autoimmune disorder * Severe active infection or other serious medical illness, that in the opinion of the Principal Investigator, would prevent study completion * Other malignancies in the past 5 years, except adequately treated in situ cervix carcinoma or non-melanoma skin cancer

Design outcomes

Primary

Measure	Time frame
The primary goal of this trial is to determine if HSPPC-96 can be made from the tumor tissue of patients with resectable non-small cell lung cancer.	—

Secondary

Measure	Time frame
The secondary goals are to further characterize the safety and efficacy profile, to evaluate disease recurrence in patients, and to evaluate overall survival in patients receiving HSPPC-96.	—

Countries

United Kingdom

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026